David T. Ting MD is a physician scientist, cancer biologist, and bioengineer. He is currently Associate Clinical Director for Innovation at the Mass General Cancer Center and Associate Professor of Medicine at Harvard Medical School. Dr. Ting received his B.S. in chemical engineering and biology from MIT, MD from Harvard Medical School, and medical oncology training at the Massachusetts General Hospital and Dana-Farber Cancer Institute. Dr. Ting’s lab works on understanding RNA expression patterns in cancer to gain biological insight into the role of tumor heterogeneity in cancer progression, develop biomarkers applicable to the clinic, and to identify novel therapeutic avenues against cancer. His group uses single cell analytics and spatial transcriptomics to understand the relationship of cancer microenvironment and tumor heterogeneity. This work has led to mechanistic understanding of aberrant expression of repeat RNAs that appear to play an important role in both the tumor microenvironment and metastasis. His work hasled to the founding of three biotech companies, PanTher Therapeutics, ROME Therapeutics, and TellBio, Inc.